Botulinum toxin therapy for skin disorders
Methods for treating skin disorders by local administration of a Clostridial toxin, such as a botulinum toxin, to a patient with a skin disorder.
1. A method for treating a keloid in a patient in need thereof, the method comprising the step of administering a therapeutically effective amount of a botulinum toxin complex to the keloid, to thereby treat the keloid; wherein the therapeutically effective amount administered is less than an amount used to paralyze a muscle, ranging between about 10 −3 units/kg of patient weight and about 35 units/kg of patient weight, and which reduces the keloid in size by from about 20% to 100%.
2. The method of claim 1 , wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G.
3. The method of claim 1 , wherein the botulinum toxin is a botulinum toxin type A.
4. The method of claim 1 , wherein the administration is by topical or subcutaneous administration of the botulinum toxin.
5. The method of claim 1 , wherein administration of a botulinum toxin type A is no less than about 1 to about 200 units per patient treatment session.
6. The method of claim 2 wherein administration of a botulinum toxin type B is no less than about 40 to about 2500 units per patient treatment session.
7. A method for treating a symptom associated with a keloid in a patient in need thereof, the method comprising the step of administering a therapeutically effective amount of a botulinum toxin complex to the keloid, thereby treating the symptom associated with the keloid, wherein the therapeutically effective amount administered is less than an amount used to paralyze a muscle, ranging between about 10 −3 units/kg of patient weight and about 35 units/kg of patient weight, and which reduces the keloid in size by from about 20% to 100%.
8. The method of claim 7 , wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G.
9. The method of claim 7 , wherein the administration is by injection directly to the keloid.
10. The method of claim 7 , wherein the symptom is selected from the group consisting of pain, inflammation and vascularization.
11. The method of claim 7 , wherein administration is transdermal or subdermal or intradermal.
12. The method of claim 7 , wherein the administration is by a botulinum toxin implant.
13. The method of claim 7 , wherein administration of a botulinum toxin type A is no less than about 1 to about 200 units per administration site, per patient treatment session.
14. The method of claim 7 , wherein administration of a botulinum toxin type B is no less than about 40 to about 2500 units per administration site, per patient treatment session.
15. A method for treating a keloid in a patient in need thereof, the method comprising the step of administering a dose of a botulinum toxin complex type A, to the keloid of the patient; wherein the dose administered is less than an amount used to paralyze a muscle, ranging between about 10 −3 units/kg of patient weight and about 35 units/kg of patient weight, and which reduces the keloid in size by from about 20% to 100%.
16. The method of claim 15 , wherein the administration is by injection directly to the keloid.
17. The method of claim 15 , wherein the administration is by topical or subcutaneous administration of the botulinum toxin.